Slitrk1-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities

Molecular Psychiatry

Volumn 15, Issue 2, 2010, Pages 177-184

  Katayama, K ^a   Yamada, K ^a   Ornthanalai, V G ^a   Inoue, T ^a   Ota, M ^a   Murphy, N P ^a   Aruga, J ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Anxiety; Depression; Leucine rich repeat; Norepinephrine; Tourette's syndrome; Trichotillomania

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; CLONIDINE; NORADRENALIN; PROTEIN; SLITRK1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; EMBRYO; FORCED SWIMMING TEST; GILLES DE LA TOURETTE SYNDROME; IMMOBILIZATION; KNOCKOUT MOUSE; MALE; MAZE TEST; MOUSE; NEUROCHEMISTRY; NONHUMAN; NORADRENERGIC SYSTEM; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TRICHOTILLOMANIA;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONIDINE; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; ELECTROCHEMISTRY; EXPLORATORY BEHAVIOR; FEAR; HINDLIMB SUSPENSION; MAZE LEARNING; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NOREPINEPHRINE; STATISTICS, NONPARAMETRIC; SWIMMING;

EID: 75549083491     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2008.97     Document Type: Article

References (41)

1. Aruga J, Mikoshiba K. Identification and characterization of Slitrk, a novel neuronal transmembrane protein family controlling neurite outgrowth. Mol Cell Neurosci 2003; 24: 117-129.
2. Aruga J, Yokota N, Mikoshiba K. Human SLITRK family genes: genomic organization and expression profiling in normal brain and brain tumor tissue. Gene 2003; 315: 87-94.
3. Kobe B, Deisenhofer J. Proteins with leucine-rich repeats. Curr Opin Struct Biol 1995; 5: 409-416.
4. Brose K, Tessier-Lavigne M. Slit proteins: key regulators of axon guidance, axonal branching, and cell migration. Curr Opin Neurobiol 2000; 10: 95-102.
5. Patapoutian A, Reichardt LF. Trk receptors: mediators of neuro-trophin action. Curr Opin Neurobiol 2001; 11: 272-280.
6. Chen Y, Aulia S, Li L, Tang BL. AMIGO and friends: an emerging family of brain-enriched, neuronal growth modulating, type I transmembrane proteins with leucine-rich repeats (LRR) and cell adhesion molecule motifs. Brain Res Brain Res Rev 2006; 51: 265-274.
7. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005; 310: 317-320.
8. Züchner S, Cuccaro ML, Tran-Viet KN, Cope H, Krishnan RR, Pericak-Vance MA et al. SLITRK1 mutations in trichotillomania. Mol Psychiatry 2006; 11: 887-889.
9. Leckman JF. Tourette's syndrome. Lancet 2002; 360: 1577-1586.
10. Robertson MM, Cavanna AE. The Gilles de la Tourette syndrome: a principal component factor analytic study of a large pedigree. Psychiatr Genet 2007; 17: 143-152.
11. Hautmann G, Hercogova J, Lotti T. Trichotillomania. J Am Acad Dermatol 2002; 46: 807-821; quiz 822-1806
12. Inoue T, Hatayama M, Tohmonda T, Itohara S, Aruga J, Mikoshiba K. Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives. Dev Biol 2004; 270: 146-162.
13. Sakai K, Miyazaki J. A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. Biochem Biophys Res Commun 1997; 237: 318-324.
14. Sadakata T, Washida M, Iwayama Y, Shoji S, Sato Y, Ohkura T et al. Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. J Clin Invest 2007; 117: 931-943.
15. Satoh Y, Endo S, Ikeda T, Yamada K, Ito M, Kuroki M et al. Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory. J Neurosci 2007; 27: 10765-10776.
16. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M et al. Genetic enhancement of learning and memory in mice. Nature 1999; 401: 63-69.
17. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979; 57: 201-210.
18. Wesolowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 2007; 52: 1274-1283.
19. Silva RH, Kameda SR, Carvalho RC, Takatsu-Coleman AL, Niigaki ST, Abilio VC et al. Anxiogenic effect of sleep deprivation in the elevated plus-maze test in mice. Psychopharmacology (Berl) 2004; 176: 115-122.
20. Pringsheim T, Davenport WJ, Lang A. Tics. Curr Opin Neurol 2003; 16: 523-527.
21. Robertson MM. Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary. Eur Child Adolesc Psychiatry 2006; 15: 1-11.
22. Schlicker E, Göthert M. Interactions between the presynaptic a2-autoreceptor and presynaptic inhibitory heteroreceptors on nora-drenergic neurones. Brain Res Bull 1998; 47: 129-132.
23. Hu H, Real E, Takamiya K, Kang MG, Ledoux J, Huganir RL et al. Emotion enhances learning via norepinephrine regulation of AMPA-receptor trafficking. Cell 2007; 131: 160-173.
24. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrener-gic mechanisms in stress and anxiety. I. Preclinical studies. Synapse 1996; 23: 28-38.
25. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.
26. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrener-gic mechanisms in stress and anxiety. II. Clinical studies. Synapse 1996; 23: 39-51.
27. Rodgers RJ, Cole JC. Effects of scopolamine and its quaternary analogue in the murine elevated plus-maze test of anxiety. Behav Pharmacol 1995; 6: 283-289.
28. Brioni JD, O'Neill AB, Kim DJ, Decker MW. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 1993; 238: 1-8.
29. Szyndler J, Sienkiewicz-Jarosz H, Maciejak P, Siemiatkowski M, Rokicki D, Czlonkowska AI et al. The anxiolytic-like effect of nicotine undergoes rapid tolerance in a model of contextual fear conditioning in rats. Pharmacol Biochem Behav 2001; 69: 511-518.
30. Weiner MF, Svetlik D, Risser RC. What depressive symptoms are reported in Alzheimer's patients? Int J Geriatr Psychiatry 1997; 12: 648-652.
31. Grados MA, Walkup JT. A new gene for Tourette's syndrome: a window into causal mechanisms? Trends Genet 2006; 22: 291-293.
32. Takeuchi H, Yatsugi S, Yamaguchi T. Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model. Jpn J Pharmacol 2002; 90: 197-200.
33. Matsushita M, Egashira N, Harada S, Okuno R, Mishima K, Iwasaki K et al. Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci 2005; 99: 154-159.
34. Kurlan R, Como PG, Miller B, Palumbo D, Deeley C, Andresen EM et al. The behavioral spectrum of tic disorders: a community-based study. Neurology 2002; 59: 414-420.
35. Robertson MM. Mood disorders and Gilles de la Tourette's syndrome: an update on prevalence, etiology, comorbidity, clinical associations, and implications. J Psychosom Res 2006; 61: 349-358.
36. Weissman MM, Fyer AJ, Haghighi F, Heiman G, Deng Z, Hen R et al. Potential panic disorder syndrome: clinical and genetic linkage evidence. Am J Med Genet 2000; 96: 24-35.
37. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002; 7: 405-411.
38. Potash JB, Zandi PP, Willour VL, Lan TH, Huo Y, Avramopoulos D et al. Suggestive linkage to chromosomal regions 13q31 and 22q12 in families with psychotic bipolar disorder. Am J Psychiatry 2003; 160: 680-686.
39. McGuffin P, Knight J, Breen G, Brewster S, Boyd PR, Craddock N et al. Whole genome linkage scan of recurrent depressive disorder from the depression network study. Hum Mol Genet 2005; 14: 3337-3345.
40. Sullivan GM, Coplan JD, Kent JM, Gorman JM. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol Psychiatry 1999; 46: 1205-1218.
41. Neumeister A, Daher RJ, Charney DS. Anxiety disorders: noradrenergic neurotransmission. Handb Exp Pharmacol 2005; 169: 205-223.